Biomea Fusion Announces BMF-219 in Diabetes Placed on
REDWOOD CITY, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), announced that ...
Read moreREDWOOD CITY, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), announced that ...
Read moreLAS VEGAS, April 29, 2024 (GLOBE NEWSWIRE) -- Leading strategy game publisher and developer Stone Blade Entertainment is breaking new ...
Read moreExpansion portion of Phase II COVALENT-111 study readout in 216 patients with type 2 diabetes expected in 2024.Open label portion ...
Read moreArtemish, the epitome of luxury and craftsmanship in the furniture industry, proudly announces its exclusive sponsorship at the renowned ...
Read moreBengaluru, Karnataka, India Bengaluru-based brand Que by M - well-known for affordable millennial jewellery is foraying into the Active ...
Read moreAt Week 26, 22 weeks after the last dose of BMF-219, the 200 mg cohorts increased the percentage of patients ...
Read moreBMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.